- Home
- GLAD vs CRVS Comparison
GLAD vs CRVS Comparison
Compare GLAD & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLAD
- CRVS
- Stock Information
- Founded
- GLAD 2001
- CRVS 2014
- Country
- GLAD United States
- CRVS United States
- Employees
- GLAD N/A
- CRVS N/A
- Industry
- GLAD Finance/Investors Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- GLAD Finance
- CRVS Health Care
- Exchange
- GLAD Nasdaq
- CRVS Nasdaq
- Market Cap
- GLAD 611.4M
- CRVS 516.0M
- IPO Year
- GLAD N/A
- CRVS 2016
- Fundamental
- Price
- GLAD $27.38
- CRVS $4.99
- Analyst Decision
- GLAD Hold
- CRVS Buy
- Analyst Count
- GLAD 1
- CRVS 4
- Target Price
- GLAD $23.00
- CRVS $12.83
- AVG Volume (30 Days)
- GLAD 133.9K
- CRVS 1.6M
- Earning Date
- GLAD 02-03-2025
- CRVS 11-12-2024
- Dividend Yield
- GLAD 7.24%
- CRVS N/A
- EPS Growth
- GLAD 89.73
- CRVS N/A
- EPS
- GLAD 4.34
- CRVS N/A
- Revenue
- GLAD $96,621,000.00
- CRVS N/A
- Revenue This Year
- GLAD $3.67
- CRVS N/A
- Revenue Next Year
- GLAD $14.13
- CRVS N/A
- P/E Ratio
- GLAD $6.31
- CRVS N/A
- Revenue Growth
- GLAD 11.79
- CRVS N/A
- 52 Week Low
- GLAD $19.20
- CRVS $1.30
- 52 Week High
- GLAD $28.40
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- GLAD 55.87
- CRVS 28.00
- Support Level
- GLAD $27.22
- CRVS $3.77
- Resistance Level
- GLAD $28.40
- CRVS $7.44
- Average True Range (ATR)
- GLAD 0.62
- CRVS 0.60
- MACD
- GLAD -0.09
- CRVS -0.41
- Stochastic Oscillator
- GLAD 51.20
- CRVS 25.85
About GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).